Vivo Capital related stories
All articles and analysis
VC-backed Aclaris goes publicMalvern, Pennsylvania-based Aclaris Therapeutics, a dermatology-focused specialty pharmaceutical company, has raised $55 million for its IPO after pricing its 5 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "ACRS." Jefferies LLC and Citigroup Global Markets Inc are serving as the lead underwriters. Aclaris is backed by Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures
- VC-backed Nabriva Therapeutics goes public
Nabriva Therapeutics, a biopharmaceutical company focused on treating serious infections, has unveiled its IPO after pricing its 9 million shares at $10.25 per share. The stock began trading Friday on the NASDAQ under the ticker symbol "NBRV." Leerink Partners LLC and RBC Capital Markets are serving as the lead underwriters. Nabriva's backers included Vivo Capital, OrbiMed EcoR1 Capital, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund
IPO of venture-backed ProNAi Therapeutics pulls in $158.4 mln in closeProNAi Therapeutics Inc has completed its previously-announced initial public offering /canada/2015/07/17/vc-backed-pronai-therapeutics-increases-ipo-target-to-138-mln/ of common shares on the NASDAQ Global Market. The company, which began trading under the symbol "DNAI" on July 16, raised a total of US$158.4 million in gross proceeds, including shares sold through the underwriters' over-allotment option. Headquartered in Vancouver, ProNAi is developing and commercializing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. It is backed by mostly U.S. venture capital firms, including Vivo Capital, Frazier Healthcare Ventures and OrbiMed Advisors.
VC-backed ProNAi Therapeutics increases IPO target to $138 mlnCanadian clinical-stage oncology specialist ProNAi Therapeutics Inc has announced the pricing of its initial public offering of common shares on the NASDAQ Global Market. The company, which expects to begin trading under the symbol "DNAI" this week, is seeking US$138 million in proceeds, which is up from its previously-disclosed target /canada/2015/06/15/venture-backed-pronai-therapeutics-files-to-raise-86-mln-on-nasdaq/ Founded in 2004, ProNAi is focused on developing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. In 2014, the Vancouver-based company raised US$59.5 million in Series D financing from mostly U.S. venture capital firms, including Vivo Capital, Frazier Healthcare Ventures and OrbiMed Advisors.
- VC-backed ProNAi files for IPO
Vancouver-based ProNAi Therapeutics, a developer of nucleic acid therapeutics, has filed for an IPO. The number of shares that will be sold as well as the stock's pricing terms have yet to be set. The stock will list on the NASDAQ under the ticker symbol "DNAI." Jefferies LLC and BofA Merrill Lynch will serve as the lead underwriters. ProNAi’s backers include Vivo Capital, Frazier Healthcare Ventures, OrbiMed Advisors, Adams Street Partners, RA Capital Management, Caxton Alternative Management, Hopen Life Science Ventures, Sectoral Asset Management and Janus Capital Management.
Venture-backed ProNAi Therapeutics files to raise $86 mln on NasdaqProNAi Therapeutics Inc, a Vancouver-based clinical-stage oncology company, has filed with the U.S. Securities and Exchange Commission (SEC) to launch an initial public offering on the Nasdaq Global Market under the ticker symbol "DNAI." According to the SEC filing, the company is seeking to raise up to US$86.2 million. Established in 2004, ProNAi is developing and commercializing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. Last year, the company secured US$59.5 million in Series D financing http://www.businesswire.com/news/home/20140421005736/en#.VX7hjvlVhHx which was led by U.S. venture capital firm Vivo Capital and was joined by existing investors. It has a research facility in Plymouth, Michigan.
- Regenxbio racks up $70.5 mln Series D
Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.
- Nabriva Therapeutics inks $120 mln Series B
Biotech company Nabriva Therapeutics AG has closed $120 million in Series B funding. Vivo Capital and OrbiMed led the round with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In addition to the funding, representatives of Vivo Capital and OrbiMed will join Nabriva's supervisory board.
- Vivo doubles fund size with $750 million Fund VIII
The healthcare focused fund beat its target
- Vivo raises $750 mln for 8th fund
Vivo Capital said it raised $750 million for its eighth fund, according to a press release and a filing with the SEC. The firm said in the release Vivo Capital Fund VIII would invest in later stage pharmaceutical and medical device companies in the United States and in expansion stage healthcare companies in China.